US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
IXICO awards share options to executives amid retention strategy
LONDON - IXICO plc (AIM:IXI), a medical imaging analytics company focused on neurosciences, has granted 850,000 share options to three executives, according to a press release statement issued Friday.
The options were awarded to Chief Technology Officer Mark Austin, Chief Business Officer James Chandler, and VP Global Business Development Terry Reilly. Austin and Chandler are classified as Persons Discharging Managerial Responsibility under Market Abuse Regulation.
The share options include vesting criteria tied to retention and annual share price growth over a three-year period. Options awarded to non-PDMR executives carry an exercise price matching the closing share price on the award date, while those granted to PDMRs have an exercise price of £0.01.
All options are subject to a mandatory hold period until the third anniversary of their award date.
Performance metrics for the options are based on share price growth, measured by calculating the three-month average share price immediately before each anniversary of the option award. The growth targets can be fully achieved through an absolute annual compound share price growth of 40% over three years, or partially through 40% growth compared to the previous year.
Separately, the company reported that Chief Financial and Operating Officer Grant Nash conducted a "bed and ISA" transaction on June 12, selling 45,263 ordinary shares and immediately repurchasing the same number into his Individual Savings Account. This transaction resulted in no change to Nash’s overall beneficial ownership in the company.
IXICO specializes in providing imaging analytics for neuroscience applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.